Latest news with #DouglasTsao
Yahoo
28-05-2025
- Business
- Yahoo
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
On May 28, H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) while keeping the price target the same at $18. The reiteration comes after the company appointed the current President and COO of Roivant, Dr. Eric Venker as CEO of Immunovant. Roivant Sciences Ltd. (NASDAQ:ROIV) is the founding parent and majority shareholder of Immunovant. A research scientist in a lab coat examining a sample of blood for sickle cell diseases. In April, the company appointed Dr. Erin Venker, M.D. as CEO of Immunovant and Tiago Girao. The analyst expects this leadership change to enhance clinical execution and strategic decision-making. Tsao believes the change will accelerate the development of the company's lead FcRn inhibitor, IMVT-1402. Additionally, IMVT-1402 is being developed for multiple high-value autoimmune indications including Graves Disease, rheumatoid arthritis, Sjögren's Disease, and more. Tsao anticipates the approval of IMVT-1402 will enhance the strategic and financial prospects of the company thereby justifying the Buy rating. Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage biopharmaceutical company that develops treatments for unmet medical needs. Its key products include VTAMA, IMVT-1402, Batoclimab, Brepocitinib, Mosliciguat, and Namilumab. While we acknowledge the potential of ROIV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ROIV and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
17-05-2025
- Business
- Business Insider
H.C. Wainwright Reaffirms Their Buy Rating on Argenx Se (ARGX)
In a report released on May 15, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price target of $720.00. The company's shares closed yesterday at $565.63. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Argenx Se, and scPharmaceuticals. According to TipRanks, Tsao has an average return of 6.8% and a 36.71% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $749.93 average price target, representing a 32.58% upside. In a report released on May 15, Stifel Nicolaus also maintained a Buy rating on the stock with a $780.00 price target. The company has a one-year high of $678.21 and a one-year low of $356.38. Currently, Argenx Se has an average volume of 412.5K.
Yahoo
21-03-2025
- Business
- Yahoo
Immunovant's batoclimab shows ‘impressive' efficacy in MG, says H.C. Wainwright
Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was encouraged to see the impressive absolute improvements in MG-Activities of Daily Living, the firm acknowledges that the placebo-adjusted readout was mid-pack among FcRn inhibitors-better than nipocalimab but below argenx's (ARGX) Vyvgart and UCB's (UCBY) Rystiggo, the analyst tells investors. The company also reported positive initial CIDP results from Period 1 of the study, which showed that following standard of care washout, patients were randomized into 680mg and 340mg batoclimab only, the firm says. The firm has a Buy rating and $51 price target on Immunovant shares, and says the 'more is better' debate has not yet been settled. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on IMVT: Questions or Comments about the article? Write to editor@ Immunovant Announces Positive Phase 3 Study Results Immunovant announces results from Phase 3 study of batoclimab in MG Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG Immunovant's Phase 3 Trial of Batoclimab: A Catalyst for Future Growth and Market Impact Biohaven price target lowered to $57 from $73 at Bernstein
